Announcement PDF ASX Announcement Upfront payment of USD $5.5 million received from Genentech ● Starpharma has received the upfront payment of USD $5.5 million (AUD $8.5 million1 ) from Genentech, in line with the recently announced license agreement2 . ● Activities have commenced on the collaborative program to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets. ● Under the agreement, Starpharma is also eligible for development, commercial and net sales milestones of up to USD $564 million (AUD $869 million1 ), as well as tiered royalties on global net sales. Melbourne, Australia; 22 October 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces that it has received the upfront payment of USD $5.5 million (AUD $8.5 million) from Genentech, a member of the Roche Group, in line with the recently announced license agreement. Under the agreement, Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines directed to selected oncology targets. Starpharma’s DEP® platform technology offers significant benefits in drug development, including improved solubility, increased efficacy, pharmacokinetic control, and improved toxicity profiles. These advantages can be applied to a wide range of drug classes, such as small molecules, peptides, and proteins, as well as to the development of chemotherapeutics, radiotheranostics, and antibody-drug conjugates. These benefits provide companies with opportunities to enhance product attributes by differentiating their portfolios and unlocking additional treatment indications. Visit Starpharma’s new Investor Hub to access the latest company developments, updates, and strategic insights, and submit questions. By joining our Investor Hub, you will gain access to commentary from CEO Cheryl Maley and resources designed to help you stay connected with Starpharma’s story. Scan the QR code or visit: https://investors.starpharma.com/link/rvJxMr 1 All contracted financial terms are denominated in US dollars. All figures denominated in AUD have been converted using a USD:AUD exchange rate of 1.54 as at 22 October 2025. 2 ASX: SPL Starpharma Announces License Agreement with Genentech dated 22 September 2025 https://investors.starpharma.com/announcements/7160519. 2 About Starpharma Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the- counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, Chief Financial and Operations Officer and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford VIC 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”,“set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is beingdeveloped”,“could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’requirements regardingany one ormore product candidates, nor can there beanyassurancethat such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products,product candidates, financial results and business prospects. Should one or more ofthese risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.